Antiviral Drug Interactions
Guidance on the Use of Influenza Antiviral Agents
This page is pending review for the 2013-2014 influenza season. However, information here should be considered current for clinical practice regarding the use of influenza antiviral medications.
This page contains excerpts from Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza - Recommendations of the Advisory Committee on Immunization Practices (ACIP).
PDF Version [1 MB, 28 pages]
Clinical data are limited regarding drug interactions with zanamivir. No known drug interactions have been reported, and no clinically critical drug interactions have been predicted on the basis of in vitro and animal study data [116, 232].
Limited clinical data are available regarding drug interactions with oseltamivir. Because oseltamivir and oseltamivir carboxylate are excreted in the urine by glomerular filtration and tubular secretion via the anionic pathway, a potential exists for interaction with other agents excreted by this pathway. For example, coadministration of oseltamivir and probenecid resulted in reduced clearance of oseltamivir carboxylate by approximately 50% and a corresponding approximate twofold increase in the plasma levels of oseltamivir carboxylate .
No published data from clinical trials are available concerning the safety or efficacy of using combinations of different classes of influenza antiviral drugs. One recent study suggested that use of oseltamivir plus zanamivir was less efficacious than monotherapy with either drug alone . Providers should consult package inserts for more detailed information about potential drug interactions.